Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31354617 | 0.83 | MAPK1 (0.39) | KDM4EL3MBTL1MAPK1MAPTALDH1A1 | |
| SCHEMBL30871848 | 0.83 | SCN10A (0.49) | KDM4EL3MBTL1POLBALDH1A1LMNA | |
| SCHEMBL5554420 | 0.81 | MAPK1 (0.46) | KDM4EMAPK1MAPTALDH1A1GAA | |
| SCHEMBL14918993 | 0.80 | KDM4E (0.71) | KDM4EL3MBTL1MAPK1MAPTALDH1A1 | |
| SCHEMBL31354558 | 0.80 | LCK (0.46) | MAPK1MAPTALDH1A1LMNAGAA | |
| SCHEMBL7226331 | 0.80 | KDM4E (0.47) | KDM4EL3MBTL1MAPK1MAPTALDH1A1 | |
| SCHEMBL12462531 | 0.80 | LCK (0.46) | MAPK1MAPTALDH1A1LMNAGAA | |
| SCHEMBL14956928 | 0.80 | ALDH1A1 (0.47) | KDM4EMAPK1MAPTALDH1A1LMNA | |
| SCHEMBL28059038 | 0.79 | L3MBTL1 (0.44) | KDM4EL3MBTL1MAPTPOLBALDH1A1 | |
| SCHEMBL18952477 | 0.79 | CYP1A2 (0.46) | KDM4EL3MBTL1MAPK1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| US-8829190-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| EP-2146989-B1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA AS (DK) | 2012-01-04 | — | — | EP | disclosed |
| EP-2146989-B1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA AS (DK) | 2012-01-04 | — | — | EP | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | FELDING JAKOB | 2010-05-06 | — | — | US | disclosed |
| EP-2146989-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | Leo Pharma A/S (DK) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008125111-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125111-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113442-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | PDE5A, PDE3A, PDE3B | KDM4E 1090/4885L3MBTL1 3852/4885MAPK1 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.